Glioblastoma (GBM) is the most deadly type of malignant brain tumor, despite extensive
molecular analyses of GBM cells. In recent years, the tumor microenvironment (TME) has …

Glioblastoma (GBM) treatment has remained almost unchanged for more than 20 years. The
current standard of care involves surgical resection (if possible) followed by concomitant …

The transfer of intact mitochondria between heterogeneous cell types has been confirmed in
various settings, including cancer. However, the functional implications of mitochondria …

In patients with glioblastoma, the average survival time with current treatments is short,
mainly due to recurrences and resistance to therapy. This insufficient treatment success is, in …

Glioblastoma (GBM) is a particularly devastating tumor with a median survival of about 16
months. Recent research has revealed novel insights into the outstanding heterogeneity of …

Glioblastoma (GBM) is the most lethal type of primary brain cancer. Standard care using
chemo-and radio-therapy modestly increases the overall survival of patients; however …

Despite aggressive multimodal treatment, glioblastoma (GBM), a grade IV primary brain
tumor, still portends a poor prognosis with a median overall survival of 12–16 months. The …

Simple Summary This review describes in a very detailed and exhaustive approach the
literature of these last 20 years on glioblastoma targeted therapies in Phases II-IV of 257 …

Glioblastoma (GBM) is the most common form of brain tumor characterized by its resistance
to conventional therapies, including temozolomide, the most widely used chemotherapeutic …

Glioblastoma (GBM) is characterized by aberrant vascularization and a complex tumor
microenvironment. The failure of anti-angiogenic therapies suggests pathways of GBM …